Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)

China · Delayed Price · Currency is CNY

10.34

+0.41 (4.13%)

Jun 29, 2026, 3:00 PM CST

11.78% (1Y)

Market Cap	11.98B +11.0%
Revenue (ttm)	10.31B +0.6%
Net Income	702.17M +28.4%
EPS	0.60 +25.0%
Shares Out	1.16B
PE Ratio	17.33
Forward PE	26.51
Dividend	0.21 (2.11%)
Ex-Dividend Date	Jun 16, 2026

Volume	31,270,796
Open	9.90
Previous Close	9.93
Day's Range	9.59 - 10.45
52-Week Range	9.11 - 13.06
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHA:600267

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small molecule, animal healthcare, and others. The company exports its products to approximately 70 countries worldwide. Zhejiang Hisun Pharmaceutical Co., Ltd.... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1956

Employees 8,751

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600267

Full Company Profile

Financial Performance

In 2025, SHA:600267's revenue was 10.55 billion, an increase of 2.03% compared to the previous year's 10.34 billion. Earnings were 540.71 million, a decrease of -10.06%.

Financial Statements